LP
TEVA icon

LMR Partners’s Teva Pharmaceuticals TEVA Stock Holding History

LMR Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-152,100
Closed -$4.75M – 1863
2025
Q4 		$4.75M Sell
152,100
-43,000
-22% -$1.06M 0.01% 585
2025
Q3 		$3.94M Sell
195,100
-388,300
-67% -$6.82M 0.02% 573
2025
Q2 		$9.78M Sell
583,400
-8,200
-1% -$132K 0.07% 296
2025
Q1 		$9.09M Buy
+591,600
New +$10.6M 0.09% 264

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's TEVA Position: Q2 2025 in Review

LMR Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 63,834 shares — an estimated $1.03M sold.

LMR Partners first reported a position in TEVA in Q4 2017 and held it in 5 quarters. The position peaked at $1.43M in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • LMR Partners reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • LMR Partners sold 63,834 Teva Pharmaceuticals shares in Q2 2025, an estimated $1.03M.
  • LMR Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • LMR Partners's Teva Pharmaceuticals position peaked at $1.43M in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.